Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of… Read More
· Up to 75% of all women are affected by vaginal infection in their lifes · Self-diagnoses leads often to unnecessary and inappropriate treatment use · This… Read More
· Important expansion of patent estate in the largest market for vaginal bacterial infections · pHyph has shown superior safety profile, a cure rate in line with… Read More
Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the… Read More
Positiv påverkan på mikrobiomet kan vara nyckeln till att förhindra återfall av vulvovaginal infektion Gedea Biotech meddelar idag att man har beviljats 3 miljoner kronor… Read More
